Cancer-associated antigens

**Cancer-associated antigens** is an umbrella term for a variety of molecules—including proteins, glycoproteins, and glycolipids—that are present on or produced by cancer cells. These antigens can be classified generally as tumor-specific antigens (unique to cancer cells) or tumor-associated antigens (overexpressed in tumors but present also on certain normal tissues)[1][3][5]. Some arise from mutated genes (neoantigens), while others reflect abnormal expression of normal proteins, embryonic development markers (oncofetal antigens), or products of oncogenic viruses. These antigens are key targets for immune-based cancer therapies, such as cancer vaccines, monoclonal antibodies, and adoptive cell therapies, but their use is limited by specificity and risk of targeting normal cells that express related antigens[1][3][5][7]. If you require structured information for a specific antigen (e.g., “MAGE-A3,” “Carbonic anhydrase IX,” “Prostate-specific antigen”), a more precise request or name is needed.

Other names

Tumor antigenTumor-associated antigen (TAA)Tumor-specific antigen (TSA)Cancer antigen

Immune recognition by T cells via MHC presentation; Antibody binding in targeted immunotherapies (for defined antigens); Induction of immune-mediated cell death (for defined antigens). The category “cancer-associated antigen” encompasses a vast set of molecules; only specific members have defined drug interactions.